Pharmacogenetics of EGFR and VEGF inhibition

Drug Discovery Today

Volumn 12, Issue 23-24, 2007, Pages 1054-1060

  Pander, Jan ^a   Gelderblom, Hans ^a   Guchelaar, Henk Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; INFLIXIMAB; PANITUMUMAB; RITUXIMAB; VASCULOTROPIN RECEPTOR;

ALLELE; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CROHN DISEASE; DRUG EFFECT; DRUG HALF LIFE; DRUG INHIBITION; DRUG RESPONSE; FOLLICULAR LYMPHOMA; GENETIC ASSOCIATION; HUMAN; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NONHUMAN; PHARMACOGENETICS; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIBODIES, MONOCLONAL; HUMANS; NEOPLASMS; PHARMACOGENETICS; RECEPTOR, EPIDERMAL GROWTH FACTOR; VARIATION (GENETICS); VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 36549047976     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.10.016     Document Type: Review

References (66)

1. Burtness B., et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group Study. J. Clin. Oncol. 23 (2005) 8646-8654
2. Hurwitz H., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 (2004) 2335-2342
3. Sandler A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355 (2006) 2542-2550
4. Garrison, L. et al. (2007) Cost comparison of XELOX compared to FOLFOX4 with or without bevacizumab (bev) in metastatic colorectal cancer. J. Clin. Oncol. 25 (Abstract 4074)
5. Sharma S.V., et al. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7 (2007) 169-181
6. Liu W., et al. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin. Cancer Res. 9 (2003) 1009-1012
7. Gregorc, V. et al. (2005) Association of germline mutations in EGFR and ABCG2 with gefitinib response in patients with non-small cell lung cancer (NSCLC). J. Clin. Oncol. 23 (Abstract 3022)
8. Etienne-Grimaldi M.C., et al. Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients. Ann. Oncol. 16 (2005) 934-941
9. Han S.W., et al. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. Pharmacogenet. Genomics 17 (2007) 313-319
10. Amador M.L., et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res. 64 (2004) 9139-9143
11. Gebhardt F., et al. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J. Biol. Chem. 274 (1999) 13176-13180
12. McKay J.A., et al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur. J. Cancer 38 (2002) 2258-2264
13. Liu W., et al. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res. 65 (2005) 46-53
14. Moriai T., et al. A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 10217-10221
15. Liu G., et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J (2007). http://www.nature.com/tpj/index.html 10.1038/sj.tpj.6500444
16. Shahbazi M., et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 359 (2002) 397-401
17. Bhowmick D.A., et al. A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res. 64 (2004) 1220-1223
18. Nagashima F.F. et al. (2007) EGFR, Cox-2, and EGF polymorphisms associated with progression-free survival of EGFR-expressing metastatic colorectal cancer patients treated with single agent cetuximab (IMCL-0144). J. Clin. Oncol. 25 (Abstract 4129)
19. Papafili A., et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 1631-1636
20. Brosens L.A., et al. Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C COX-2 polymorphism. Clin. Cancer Res. 11 (2005) 4090-4096
21. Cipollone F., et al. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 291 (2004) 2221-2228
22. Lievre A., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66 (2006) 3992-3995
23. Di Fiore F., et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br. J. Cancer 96 (2007) 1166-1169
24. Moroni M., et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 6 (2005) 279-286
25. Hull J., et al. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax 55 (2000) 1023-1027
26. Renzoni E., et al. Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum. 43 (2000) 1633-1640
27. Izzo J.G., et al. Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. J. Clin. Oncol. 25 (2007) 698-707
28. Zhang W., et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet. Genomics 16 (2006) 475-483
29. Ferrara N., and Kerbel R.S. Angiogenesis as a therapeutic target. Nature 438 (2005) 967-974
30. Brogan I.J., et al. Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. Hum. Immunol. 60 (1999) 1245-1249
31. Watson C.J., et al. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12 (2000) 1232-1235
32. Renner W., et al. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J. Vasc. Res. 37 (2000) 443-448
33. Krippl P., et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int. J. Cancer 106 (2003) 468-471
34. Koukourakis M.I., et al. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46 (2004) 293-298
35. Shahbazi M., et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J. Am. Soc. Nephrol. 13 (2002) 260-264
36. Stevens A., et al. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 63 (2003) 812-816
37. Awata T., et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51 (2002) 1635-1639
38. Howell W.M., et al. Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun. 3 (2002) 229-232
39. Jin Q., et al. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin. Cancer Res. 11 (2005) 3647-3653
40. Lee S.J., et al. Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 571-575
41. Lu H., et al. Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res. 65 (2005) 5015-5019
42. Kariyazono H., et al. Association of vascular endothelial growth factor (VEGF) and VEGF receptor gene polymorphisms with coronary artery lesions of Kawasaki disease. Pediatr. Res. 56 (2004) 953-959
43. Tanimoto K., et al. Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 24 (2003) 1779-1783
44. Yamada N., et al. Genetic variation in the hypoxia-inducible factor-1alpha gene is associated with type 2 diabetes in Japanese. J. Clin. Endocrinol. Metab. 90 (2005) 5841-5847
45. Koukourakis M.I., et al. C2028T polymorphism in exon 12 and dinucleotide repeat polymorphism in intron 13 of the HIF-1alpha gene define HIF-1alpha protein expression in non-small cell lung cancer. Lung Cancer 53 (2006) 257-262
46. Fu X.S., et al. Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate 63 (2005) 215-221
47. Kuwai T., et al. Expression of hypoxia-inducible factor-1alpha is associated with tumor vascularization in human colorectal carcinoma. Int. J. Cancer 105 (2003) 176-181
48. Junghans R.P., and Anderson C.L. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 5512-5516
49. Sachs U.J., et al. A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor alpha-chain promoter. Immunology 119 (2006) 83-89
50. Koene H.R., et al. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 90 (1997) 1109-1114
51. Wu J., et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J. Clin. Invest. 100 (1997) 1059-1070
52. Dall'Ozzo S., et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 64 (2004) 4664-4669
53. Cartron G., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 (2002) 754-758
54. Weng W.K., and Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21 (2003) 3940-3947
55. Louis E., et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment. Pharmacol. Ther. 19 (2004) 511-519
56. Louis E.J., et al. Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study. Pharmacogenet. Genomics 16 (2006) 911-914
57. Zhang W., et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J. Clin. Oncol. 25 (2007) 3712-3718
58. Feuk L., et al. Structural variation in the human genome. Nat. Rev. Genet. 7 (2006) 85-97
59. Sebat J., et al. Large-scale copy number polymorphism in the human genome. Science 305 (2004) 525-528
60. Iafrate A.J., et al. Detection of large-scale variation in the human genome. Nat. Genet. 36 (2004) 949-951
61. Zhang J., et al. Development of bioinformatics resources for display and analysis of copy number and other structural variants in the human genome. Cytogenet. Genome Res. 115 (2006) 205-214
62. Lenz H.J., et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J. Clin. Oncol. 24 (2006) 4914-4921
63. Fanciulli M., et al. FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat. Genet. 39 (2007) 721-723
64. Hirsch F.R. EGFR: a prognostic and/or a predictive marker?. J. Thorac. Oncol. 1 (2006) 395-397
65. Vallbohmer D., et al. Molecular determinants of cetuximab efficacy. J. Clin. Oncol. 23 (2005) 3536-3544
66. Vincenzi B., et al. Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan. Pharmacogenomics 8 (2007) 319-327